Skip to content

Current Research

Studies

ASAP ECMO

Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO

This is a multi-centre, open-label, descriptive pharmacokinetic (PK) study.


LIFEGARDS

VentiLatIon management oF patients with Extracorporeal membrane oxyGenation for Acute Respiratory Distress Syndrome

LIFEGARDS is a multicenter, observational study assessing the mechanical ventilation management of patients with ARDS undergoing ECMO, in a worldwide population over a one-year period.


 

EOLIA

ECMO to rescue Lung Injury in severe ARDS

EOLIA is a multicenter, international, randomized, controlled trial run by the REVA network and endorsed by the International ECMO Network. The study hypothesizes that ECMO, instituted early after the diagnosis of very severe ARDS (P:F < 80), would lower the morbidity and mortality associated with this syndrome. This study is closed.


REST

PRotective vEntilation with veno-venouS lung assisT in respiratory failure

Randomized, allocation concealed, controlled, open, phase 3 pragmatic clinical effectiveness trial to determine whether VV-ECCO2R in mechanically ventilated patients with acute hypoxaemic respiratory failure in intensive care improves mortality at 90 days.


SOLVE ARDS

Strategies for Optimal Lung Ventilation in ECMO for ARDS

To assess if a CPAP strategy that minimizes end-tidal pulmonary stress/strain mitigates VILI in comparison to current MV using tidal ventilation in severe ARDS patients on VV ECMO.


SUPERNOVA

Strategy of UltraProtective lung ventilation With Extracorporeal CO2 Removal for New-Onset moderate to seVere ARDS

SUPERNOVA is an ESICM-sponsored trial which has been endorsed by the International ECMO Network. This study assessed changes in pH / PaO2 /PaCO2, Respiratory Rate and device CO2 clearance in the first 24 hours of ECCO2R following VT and plateau pressure reduction in patients with moderate ARDS. Safety variables during treatment will also be analyzed. This study is closed.


IDEA

ImmunoDeficiency and ECMO for Acute respiratory failure

This study will provide, for the first time, detailed descriptive data on the characteristics, the complication and the outcome of adult’s immunocompromised patients receiving ECMO for ARDS. This study is closed


XXL

Gas eXchange eXtracorporeaL techniques: How many candidates in the ICU?

Prospective, observational study screening patients that meet criteria for ECLS to evaluate the incidence of patients who may be candidates for the different forms of extracorporeal support in ICU.


VENT-AVOID

A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support

This study is being conducted under an FDA approved IDE to establish the safety and efficacy of an investigational Class III medical device for FDA pre-market approval (PMA) via a pivotal RCT to scientifically validate the indication for its use in acute exacerbation of COPD.  The primary objective is to demonstrate the safety and efficacy of using the Hemolung RAS to provide low-flow ECCO2R as an alternative or adjunct to invasive mechanical ventilation versus standard of care invasive mechanical ventilation alone to increase ventilator-free days for COPD patients who require respiratory support due to an acute exacerbation of their COPD.

 


OBLEX

 


Sub30 pilot

 


MORE-PT

 


PROTECMO

Prospective multicenter Observational study on Transfusion practice in vv-ECMO Patients: The PROTECMO Study is a prospective observational multicenter cohort study. The principal aim is to describe current effective blood product usage, during VV-ECMO. The secondary aim is to describe in a large cohort of ECMO patients the current anticoagulation strategy and bleeding episodes occurrence.

 


ECMO PT

ECMO PT is a multicentre, randomised, trial of whether early individualised physical training (commenced within first 48 hours of ECMO) is feasible and improves functional recovery (the highest level of activity and duration) compared to standard care in ECMO patients.

 


 

Surveys
Scroll To Top